BioSpace News Archive

Noxopharm (ASX: NOX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM).

MKJ Brands LLC in conjunction with My Sales LLC announced that they have re-launched Modess® Feminine Hygiene products.

These foreign health products have been found by regulators in the United States, Singapore, Australia and Hong Kong to contain undeclared drug ingredients, which may pose serious health risks.

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the closing of its public offering of 9,324,324 shares of its common stock at a price to the public of $18.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,216,216 shares of common stock.

As a precautionary measure, Sanofi will conduct a voluntary recall of Zantac OTC in the U.S. and Canada.

Sei Bello, a plastic surgery center in Lawrenceville, Ga., announced today its adoption of Sensus Healthcare’s Superficial Radiation Therapy, or SRT, for the treatment of keloids, a type of raised scar that forms on an area of the skin that has healed from an injury, such as a C-section or ear piercing.

American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the disease.

Lawsuits Filed Over Contaminated Talcum Power Gain Momentum with New Study

The report, spasticity treatment market 2019-2023, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type and geography for the forecast period 2019-2023.

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that on October 15, 2019, the Company granted four new employees options to purchase a total of 411,000 shares of the Company’s common stock